MetaCap

BridgeBio Oncology Therapeutics (BBOT) vs Atrium Therapeutics (RNA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Atrium Therapeutics is the larger company by market cap ($149.3 million vs $145.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBOT-81.95%RNA-53.08%
+17%-35%-87%
Feb 27, 20261 yearNov 20, 2026
BBOT-81.95%RNA-53.08%
+8%-39%-86%
Feb 23, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBOT versus RNA key metrics
MetricBBOTRNA
Share price$1.81$6.92
Market cap$145.25M$149.27M
1-day change-2.69%-0.86%
YTD return-85.54%—
1-year return-85.39%—
P/E ratio (TTM)3.42—
EPS (TTM)$0.53$-5.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-134.04M—
52-week high$14.87$16.77
52-week low$1.79$6.36
Distance from 52-week high-87.83%-58.74%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1060.22%+217.92%
Average volume631.56K297.20K
Shares outstanding80.25M21.57M
Employees92—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BridgeBio Oncology Therapeutics

BBOT stock →

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.

Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees

About Atrium Therapeutics

RNA stock →

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.

Health Care · Biotechnology: Pharmaceutical Preparations

BBOT vs RNA FAQ

Which is bigger, BridgeBio Oncology Therapeutics or Atrium Therapeutics?

Atrium Therapeutics (RNA) is larger, with a market capitalization of $149.27M compared with $145.25M for BridgeBio Oncology Therapeutics (BBOT).

Are BridgeBio Oncology Therapeutics and Atrium Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons